|
|
 |
| (Jenna O’Malley/PitchBook News) |
|
|
Polsia, an AI agent orchestration startup, had its agent of the same name raise a $30 million funding round at a $250 million valuation this month.
Ben Broca, Polsia's founder, “just showed up for signatures” in the whole process, he quipped on X.
Broca’s startup is an extreme example of a real, emerging trend. Founders are offloading much of the legwork of fundraising to AI agents and finding they still get results, however imperfect.
“The marketing stunt around AI-led fundraising created real product traction,” Broca told PitchBook. “Revenue was going up, the live dashboard was going up, and I literally didn't have time to reply to investors myself.”
Though he let his agent do the heavy lifting, Broca still played a hand in negotiating terms, tweaking its outreach, and meeting with the most promising investors.
The AI agent swarm is creating new tensions at the negotiation table. For founders, the fundraising process is increasingly high-volume and impersonal; for investors, agentic communication can come across as rude or even insulting.
I'm Rosie Bradbury, and this is The Weekend Pitch. You can reach me at rosie.bradbury@pitchbook.com or on LinkedIn.
AI agents becoming advanced enough to even attempt fundraising is a very new phenomenon. As investors are increasingly experimenting with—and even relying on—AI agents to evaluate companies, map a competitive landscape, and conduct due diligence, founders are grappling with a central question: optimize for AI or double down on remaining "human"? |
|
|
|
|
|
| |
| A MESSAGE FROM NEXTGEN SCIENTIFIC |
|
|
| He sold his last company for $300M. Cancer research is the encore. |
|
Chemist Gene Zaid built Jacam Chemicals, sold it for $300 million in 2013, and could have stopped there. Instead, he put the money into cancer research, rooted in a remedy used for centuries near Jerusalem. That work became NextGen Scientific. Two drugs are now in FDA trials, one a capsule for cancer and one a topical for precancerous skin conditions. The likely exit is a deal with a larger pharma company. Accredited investors can review the offering now.
See if you qualify |
|
|
|
|
|
| |
Which was the largest PE fund to close in Q1 2026?
A) Triton Fund VI (Triton Partners)
B) Blackstone Life Sciences VI (Blackstone)
C) Greenbriar Equity Fund VII (Greenbriar Equity Group)
D) Inflexion Buyout Fund VII (Inflexion Private Equity Partners)
Find your answer at the bottom of The Weekend Pitch! |
|
|
|
|
|
A selection from our most-read articles of the past few days.
- Music rights are hitting all the right notes for private capital—from Blackstone's $4bn exit from a catalog including Beyoncé to Bill Ackman's $64bn UMG bid, institutional money is moving well beyond passive royalty streams. Read it now
- Efforts by advisers and consultants to cash in on the wealth channel are fueling demand for institutional-grade research capabilities to meet the needs of small but highly capitalized investors. Find out more
- Anthropic's valuation officially surpassed OpenAI's for the first time, as the company confirmed a Series H at a $965 billion valuation, making it the most valuable startup in the world. See more
|
|
|
|
|
|
 |
| (Ronaldo Schemidt/Getty Images) |
|
|
“It's going to attract larger institutional investors, as well as index funds, sooner than it would of any IPO of this nature. Well, I can’t say ‘this nature’ because no such things exist in the market … because of the size and sheer scale of this, they really need all of these accelerants for the stock to perform.”
—Jawad Hussain, senior managing partner of advisory firm Highspring, speaking about SpaceX's upcoming mega-IPO. The offering will not have the typical 180-day lockup for existing investors, instead implementing a tiered release schedule to pace sales from its oldest shareholders. Read more about SpaceX's IPO here. |
|
|
|
|
|
Answer: A
Triton Partners' Triton Fund VI was the largest PE fund to close in Q1 2026. The fund closed on $6.5 billion, narrowly edging out Blackstone's $6.3 billion close for Blackstone Life Sciences VI, according to our Q1 2026 Global Private Market Fundraising Report. Read more about PE's capital concentration here. |
|
|
|
|
|
Sign up for our newsletter
|
|
This edition of The Weekend Pitch was written by Rosie Bradbury and Nadine Manske. It was edited by Kia Kokalitcheva and Nadine Manske.
Were you forwarded The Weekend Pitch? Sign up at pitchbook.com/subscribe. |
|
|
|
|
|
| |
| Since yesterday, the PitchBook Platform added: |
|
11
Deals
|
153
People
|
119
Companies
|
|
|
| | | | |
